A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BACKGROUND: Metastasis directed therapy (MDT) for patients with oligometastatic disease is associated with improvements in progression free survival (PFS) and overall survival (OS) compared to systemic therapy alone. Additionally, within a prostate-cancer-specific cohort, MDT is able to forestall in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Hasan, Hamza, Deek, Matthew P., Phillips, Ryan, Hobbs, Robert F., Malek, Reem, Radwan, Noura, Kiess, Ana P., Dipasquale, Shirl, Huang, James, Caldwell, Terry, Leitzel, Jessica, Wendler, Danielle, Wang, Hao, Thompson, Elizabeth, Powell, Jonathan, Dudley, Sara, Deville, Curtiland, Greco, Stephen C., Song, Daniel Y., DeWeese, Theodore L., Gorin, Michael A., Rowe, Steven P., Denmeade, Sam, Markowski, Mark, Antonarakis, Emmanuel S., Carducci, Michael A., Eisenberger, Mario A., Pomper, Martin G., Pienta, Kenneth J., Paller, Channing J., Tran, Phuoc T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Study Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7268477/
https://ncbi.nlm.nih.gov/pubmed/32487038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07000-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi